ATP1B1 and hepatocellular carcinoma: Our result revealed that HCC patients with sorafenib-resistant have higher ATP1B3 expression compared to HCC patients with sorafenib-sensitive, suggesting that ATP1B expression is associated with sorafenib-resistant in HCC patients.